![Hmga1 is required for progression of chronic MPN to MF in JAKV617F-mutant mice. (A) Red blood cell (RBC) count and hemoglobin (Hb) (mean ± standard deviation [SD]) in PB from 10- to 12-week-old WT, JAK2V617F, and JAK2V617F/Hmga1+/− mice. (B) Representative spleens (left panel) and graph showing relative spleen sizes (right panel; mean ± SD) in WT, JAK2V617F, and JAK2V617F/Hmga1+/− mice. (C) Platelet (PLT) count from 40- to 60-week-old JAK2V617F and JAK2V617F/Hmga1+/− mice. (D) Megakaryocytes per high-power field (Mks/HPF) in BM from JAK2V617F and JAK2V617F/Hmga1+/− mice (left panel). MF scores in BM (middle panel) and spleen (right panel) from JAK2V617F and JAK2V617F/Hmga1+/− mice. (E) Representative images from mouse models stained with hematoxylin and eosin (H&E of BM from femurs; left panels), CD61 by immunohistochemistry (BM from femurs; left middle panels), fibrosis (BM reticulin stain; right middle panels) and splenic fibrosis (reticulin; right panels)). Scale bar, 50 μm. (F) Representative images of BM from the femurs of WT, JAK2V617F, and JAK2V617F/Hmga1+/− mice (H&E stain). Scale bars, 250 μm. Data in (A-D) are mean ± standard deviation. *P < .05, **P < .01, ***P < .001, 1-way ANOVA, followed by Tukey’s multiple-comparison test (A [right panel]), Kruskal-Wallis test, followed by Dunn’s multiple-comparison test (A [left panel], B), Mann-Whitney U test (C), 2-tailed Student t test (D). ns, not significant.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/139/18/10.1182_blood.2021013925/4/bloodbld2021013925f2.png?Expires=1725002975&Signature=jSLz2mUOzuniD86-0r9LP62~ZNBfGroH~czqM8-2tBpQd4Lpu2j2JI2bwi66UhC8RyrLott7Kx0OF7Xd-engDZIxuDi0AbwNe0YhBZFvVvfn4-rG6OoU0cm4GaROZgH-j3jgzwJriNPYlCIpFvzaAiJycxqNQ~K-ei60WlbPqtgt3PE-VoOSERjfZYZ-jF0XPM~Fu4gfgV0UagdslxQ8woIOLppOBn94-KZHSQWxuLf9yWYCDhkCNqdNCbd2rs-rxLIo1cuuhT7k0I0SCzciVlknWUJmACcAlCCrEw8eIhY7N~jt-KZnp2hJ3kpgQNgdYmtGnAi2B1c6dtiJ4iaPng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Hmga1 is required for progression of chronic MPN to MF in JAKV617F-mutant mice. (A) Red blood cell (RBC) count and hemoglobin (Hb) (mean ± standard deviation [SD]) in PB from 10- to 12-week-old WT, JAK2V617F, and JAK2V617F/Hmga1+/− mice. (B) Representative spleens (left panel) and graph showing relative spleen sizes (right panel; mean ± SD) in WT, JAK2V617F, and JAK2V617F/Hmga1+/− mice. (C) Platelet (PLT) count from 40- to 60-week-old JAK2V617F and JAK2V617F/Hmga1+/− mice. (D) Megakaryocytes per high-power field (Mks/HPF) in BM from JAK2V617F and JAK2V617F/Hmga1+/− mice (left panel). MF scores in BM (middle panel) and spleen (right panel) from JAK2V617F and JAK2V617F/Hmga1+/− mice. (E) Representative images from mouse models stained with hematoxylin and eosin (H&E of BM from femurs; left panels), CD61 by immunohistochemistry (BM from femurs; left middle panels), fibrosis (BM reticulin stain; right middle panels) and splenic fibrosis (reticulin; right panels)). Scale bar, 50 μm. (F) Representative images of BM from the femurs of WT, JAK2V617F, and JAK2V617F/Hmga1+/− mice (H&E stain). Scale bars, 250 μm. Data in (A-D) are mean ± standard deviation. *P < .05, **P < .01, ***P < .001, 1-way ANOVA, followed by Tukey’s multiple-comparison test (A [right panel]), Kruskal-Wallis test, followed by Dunn’s multiple-comparison test (A [left panel], B), Mann-Whitney U test (C), 2-tailed Student t test (D). ns, not significant.